Who is Hikma? It’s simple. We create high-quality medicines and make them accessible to the people who need them. That’s what we do.
Its what every one of our 9,400+ employees helps us to do. It’s what we’ve always done… ever since we began almost 50 years ago. Today, our headquarters are in London, but you will also find us in North America, Europe and the MENA region. With 3 main R&D locations, 29 manufacturing plants, with an established commercial infrastructure in our markets, we are global experts with a local presence. Across our sites we’re developing, manufacturing, and making available high-quality medicines for healthcare professionals and patients. 825+ products worldwide (as of Feb 2026) billions of doses annually.
Living our culture of progress and belonging.
Delivering our strategy.
Acting responsibly.
We turn cutting-edge science into innovative everyday solutions that transform people’s lives and make the world healthier.
Committed to quality.
Committed to people.
Committed to better health.
Better health. Within reach. Every day. We are Hikma
Discover what drives us
Latest news
Hikma delivers Group revenue and profit growth and announces share buyback and leadership changes
- Hikma launches Diazepam Injection, USP in the US Press Release, Product 08 July 2026 Hikma launches Diazepam Injection, USP in the US
- Hikma launches XCOPRI® (Cenobamate tablets) in the UAE Press Release, Product 06 July 2026 Hikma launches XCOPRI® (Cenobamate tablets) in the UAE
- Hikma welcomes FDA approval of Guardant360® Liquid CDx Press Release, Product 22 June 2026 Hikma welcomes FDA approval of Guardant360® Liquid CDx
- Behind Better Health: Hikma's People Insight, Life at Hikma 22 June 2026 Behind Better Health: Hikma's People
